SRF board approves Rs 180 Cr Pharma Intermediate Plant at Dahej

Capex & Operations View source PDF Explain this filing

SRF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹2854.00

prior close

₹2802.60

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.0%-5.1% vs market

Specialty Chemicals peers, median of 86sector-0.6%-5.6% vs sector

On the reaction day the stock moved 5.1 pts less than Nifty Midcap 150 and 5.6 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.3

15m

-2.1

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1-1.0-5.1-0.6-5.6

Next day

-4.2+0.2-4.4+0.0-4.2

-4.6-1.5-3.1-1.1-3.5

-5.9-1.0-4.9-1.8-4.2

-0.7+0.6-1.3-0.1-0.6

-1.4+0.7-2.1-0.4-0.9

-1.8-0.4-1.4-0.1-1.7

15d

-0.4+4.3-4.7+3.9-4.4

-8.0+2.6-10.6+0.4-8.4

-16.5-8.9-7.6-12.1-4.3

-13.7+3.8-17.4+1.2-14.9

UpDownMarket · Nifty Midcap 150Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SRF Limited board has approved setting up a new Pharma Intermediate Plant (PIP-2) at Dahej, Gujarat for undertaking precursor processes for production of pharma products. The project is estimated at Rs 180 Crores and is targeted for completion by September 30, 2026. Funding will come from a mix of debt and internal accruals. Existing capacity details are not applicable, indicating this is a fresh facility. The move is aimed at tapping new and upcoming business opportunities in the pharma space.

Likely market impact

Capacity addition may support future revenue growth from the pharma intermediates segment once commissioned by September 2026.